Holen Sie sich die Stockscreener-App
1.53
25.18%
-0.515
Vorhandelsmarkt:
1.52
-0.01
-0.65%
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
Candlestick signals on KALA BIO Inc. stock todayBreakout Watch & Verified Technical Trade Signals - newser.com
KALA BIO, Inc. Securities Lawsuit Investigation - Claim Depot
Kala Bio Shares Fall After Downgrade From Mizuho - MarketScreener
A Heavy Trading Day Sends Biotech And Finance Stocks Reeling - Finimize
Kala Bio Faces Diminishing Options After Eye Drug Failure - insights.citeline.com
Mizuho Downgrades KALA BIO to Neutral From Outperform, Price Target is $1.50 - MarketScreener
Kala Bio tanks on Phase IIb KPI-012 miss - The Pharma Letter
KALA BIO (NASDAQ:KALA) Downgraded to Hold Rating by Lifesci Capital - MarketBeat
Forecasting KALA BIO Inc. price range with options dataJuly 2025 Movers & High Yield Equity Trading Tips - newser.com
Kala Bio Halts Eye Drug Development After Phase 2b Trial Failure - Medical Dialogues
Is KALA BIO Inc. meeting your algorithmic filter criteriaJuly 2025 Market Mood & Reliable Entry Point Alerts - newser.com
Electronic Arts, Kala Bio, Semtech - TradingView
KALA BIO (KALA) Price Target Increased by 23.00% to 31.36 - Nasdaq
KALA BIO (NASDAQ:KALA) Receives “Neutral” Rating from HC Wainwright - Defense World
Can KALA BIO Inc. stock surprise with earnings upsideJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com
Is KALA BIO Inc. stock supported by strong cash flowsTrade Exit Summary & Reliable Price Breakout Alerts - newser.com
Quantitative breakdown of KALA BIO Inc. recent moveWeekly Trend Report & Safe Entry Point Identification - newser.com
Market Today: EA's Historic LBO and KALA BIO's Plunge - GuruFocus
KALA BIO Announces Topline Results from CHASE Phase 2b - GlobeNewswire
Biotech company to lay off half its workforce after eye drug fails trial - The Business Journals
KalaBio (KALA) Halts KPI-012 Development After Disappointing Tri - GuruFocus
HC Wainwright Downgrades KALA BIO to Neutral From Buy; Shares Plunge - MarketScreener
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings - Benzinga
Kala Bio stock plunges after failed Phase 2b trial for eye treatment - Investing.com
KALA Stock Falls Sharply After KPI-012 Clinical Trial Disappointment - GuruFocus
Arlington biotech slashes workforce in half after trial failure - The Business Journals
Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday? - Benzinga
Kala Bio Stock Just Plunged 92% Today – Here’s What Happened - Asianet Newsable
KALA Bio (KALA) Stock Plummets 92% After Failed Trial - GuruFocus
Nasdaq Jumps 150 Points; US Pending Home Sales Rise - Benzinga
KALA Bio's KPI-012 Fails Phase 2b CHASE Study; Shares Plunge Over 90% In Pre-Market - Nasdaq
KALA's Phase 2b Trial of KPI-012 Falls Short of Key Milestones - GuruFocus
KALA BIO plunges 92% after phase 2 failure of eye condition drug - Seeking Alpha
Kala Pharmaceuticals Halts KPI-012 Development After Trial Failure - TipRanks
Kala Bio’s corneal treatment fails to meet primary endpoint in trial - Investing.com
Kala Bio plunges after scrapping development of lead drug - MarketScreener
Kala Bio announces topline results from Chase phase 2b clinical trial - MarketScreener
KALA BIO scraps development of eye disease drug after trial failure - MarketScreener
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Yahoo Finance
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):